


iFuse Trauma™ Fix. Fuse. Fortify.™


Minimally Invasive Sacroiliac (SI) Fusion for Pelvic Ring Fractures




SI-BONE®

Fractures of the Pelvic Ring


Patient Presentation



Case 1 Preop: MVA, multiple pelvic fractures, left SI joint dislocation



Case 2 Preop: MVA, multiple pelvic fractures, 3 years postop, developed right SI joint pain




Case 3 Preop: Fall, bilateral sacral fractures, U-type¹, bed bound 2 weeks


Clinical Need

High Energy Fractures and Post-Acute SI Joint Dysfunction

- Patient outcomes after traumatic disruption of the SI joint are directly correlated to the quality of SI reduction²⁻⁴
- Up to 85% of SI trauma patients develop SI joint pain and poor function due to post-traumatic arthritis or malreduction⁵⁻¹³



Type B Sacral Fractures¹



Low Energy Fractures

Complications with nonsurgical management:

- 14-45 day average hospital stay¹⁴⁻¹⁶
- 29-61% risk of thromboembolic disorder^{17,18}
- 14-27% mortality rate at 1 year^{14,16}

Complications with surgical management:

- 20% risk of iliosacral screw backout¹⁹
- 32% risk of extravasation in sacroplasty procedures²⁰

Surgical Treatment

High Energy Fractures



Case 1 Postop: Lag screw + 2 iFuse-3D 2.5 years out, VAS 1/10, radiographic fusion, returned to manual labor

Post-Acute SI Joint Dysfunction



Case 2 Postop: Transiliac screw + 2 iFuse 1 year out, VAS 0-3/10, radiographic fusion, returned to job as nurse

Low Energy Fractures



Case 3 Postop: Transiliac screw + 4 iFuse-3D, 2 weeks out, able to sit up and participate in PT

Fix.


- **Triangular** implant geometry provides immediate **stabilization**
- Unique design provides **press fit fixation** between the implant and adjacent osseous walls
- **31x greater rotational resistance** vs. 7.3mm screw²¹

Fuse.

- **3D printed** trabecular surface facilitates **osteointegration**²²
- **Fenestrated structure** allows for bone through growth and accommodates bone graft²²
- Porous surface **self harvests bone** during insertion²²

Fortify.

- Rigid titanium construction provides an implant that is 18x stronger than the worst-case physiologic load, thus **fortifying** the SI joint²³
- **More than 5x fewer revisions** after fusion with iFuse vs. iliosacral screws²⁴



Commitment to Clinical Evidence*

More than **90 Published** Articles

90+ peer-reviewed published articles have reported on the safety, effectiveness, biomechanics and economic benefits of the iFuse Implant.

Two Level 1 RCTs

Available since 2009, iFuse is the only SI joint fusion device with published results from multiple randomized controlled trials.^{25, 26}

Long-term 5-year Data

iFuse is the only SI joint fusion device with long-term 5-year data showing durable improvement in pain, patient function, and quality of life.^{27, 28}

*Clinical evidence supporting the iFuse implant for SI joint fusion is drawn from use of the device in the non-acute setting (i.e., SI joint disruption and degenerative sacroiliitis).

References

1. Bakker G, et al. *J Korean Neurosurg Soc.* 2018;61(2):258–266. doi:10.3340/jkns.2017.0188
2. Papakostidis C, et al. *Int Orthop.* 2009;33(2):329–338. doi:10.1007/s00264-008-0555-6
3. Hoffmann MF, et al. *Clin Orthop.* 2012;470(8):2161–2172. doi:10.1007/s11999-012-2247-1
4. Dujardin FH, et al. *J Orthop Trauma.* 1998;12(3):145–150; discussion 150–151.
5. Monahan PR, et al. *Injury.* 1975;6(4):325–333.
6. Henderson RC. *J Orthop Trauma.* 1989;3(1):41–47.
7. Keating JF, et al. *J Orthop Trauma.* 1999;13(2):107–113.
8. Browner BD, et al. *J Trauma.* 1987;27(9):998–1006.
9. Kabak S, et al. *J Orthop Trauma.* 2003;17(8):555–562.
10. Tile M. *J Bone Joint Surg Br.* 1988;70(1):1–12.
11. Leung KS, et al. *Injury.* 1992;23(1):31–37.
12. Gerbershagen HJ, et al. *J Trauma.* 2010;69(1):128–136. doi:10.1097/TA.0b013e3181bbd703
13. Lindahl J, et al. *Acta Orthop.* 2005;76(5):667–678. doi:10.1080/17453670510041754
14. Taillandier J, et al. *Joint Bone Spine.* 2003;70(4):287–289.
15. Breuil V, et al. *Joint Bone Spine.* 2008;75:585–8.
16. Morris R, et al. *Postgrad Med J.* 2000;76 (900):646–50.
17. Babayev M, et al. *Am J Phys Med Rehabil.* 2000;79:404–09.
18. Geerts WH, et al. *N Engl J Med.* 1994;331:1601–6.
19. Eckardt H, et al. *Injury.* 2017;48(12):2717–23.
20. Bastian JD, et al. *Acta Orthop Belg.* 2012 Feb;78(1):100–5.
21. SI-BONE Technical Study 300191-TS
22. MacBarb RF, et al. *Int J Spine Surg.* 2017;11:16. doi:10.14444/4016
23. SI-BONE Report #300460-R
24. Spain K, et al. *Int J Spine Surg.* 2017;11:5. doi:10.14444/4005
25. Polly DW, et al. *Int J Spine Surg.* 2016;10:Article 28. doi:10.14444/3028
26. Dengler J, et al. *J Bone Joint Surg Am.* 2019;101(5):400–411. doi:10.2106/JBJS.18.00022
27. Vanaclocha V, et al. *Neurosurgery.* 2018 Jan 1;82(1):48–55. doi: 10.1093/neurology/nyx185
28. Whang PG, et al. *Med Devices Evid Res.* 2019;12:411–422 doi:10.2147/MDER.S219862

iFuse Trauma™

Fix. Fuse. Fortify.™



For Minimally Invasive
Sacroiliac Fusion

Indications

The iFuse Implant System® is intended for sacroiliac joint fusion, including use in high and low energy fractures of the pelvic ring. SI-BONE recommends that surgeons reduce and stabilize fractures (i.e., via conventional techniques such as screw fixation) prior to placement of the iFuse implant.

There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For indications, risk, and safety information about the iFuse Implant System visit www.si-bone.com/label

A list of additional published studies is available at www.si-bone.com/results

One or more of the individuals named herein may be a past or present SI-BONE employee, paid consultant, investor, clinical trial investigator, or grant recipient.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc.
iFuse Trauma and Fix. Fuse. Fortify. are trademarks of SI-BONE, Inc.
©2021 SI-BONE, Inc. All rights reserved. Patents www.si-bone.com



OUS

PROVIDERS

10657.012821 (EU)

February 2021

Importers:
SI-BONE S.r.l. European Headquarters

Via Postcastello, 6
21013 Gallarate (VA),
Italy
t +39 0331 1561179
infoeurope@si-bone.com

SI-BONE UK Ltd.

Unit 7b, St James Business Park
Knaresborough, North Yorkshire
HG5 8QB, UK
t +44 1423 860025
InfoUK@si-bone.com

SI-BONE Deutschland GmbH

Soldnerstraße 11
D - 68219 Mannheim,
Germany
t +49 (621) 976860 00
infodeutschland@si-bone.com

SI-BONE France

6 Rue des Merisiers
FR-68920 Wettolsheim les Erlen,
France
t +33 (0)9 73 79 03 92
france@si-bone.com



MedPass SAS

95 bis boulevard Pereire
75017 Paris, France
t +33 (0)1 42 12 28 84

si-bone.com



SI-BONE, Inc.

471 El Camino Real,
Suite 101
Santa Clara, CA 95050
USA
t 408.207.0700
f 408.557.8312
info@si-bone.com
www.si-bone.com